Search
BioMarin Pharmaceutical Inc
BMRNAdd to Watchlist
55.900USD
+1.210+2.21%
Close 06/22, 16:00（ET）Quotes delayed by 15 min
10.75BMarket Cap
40.07P/E TTM
Revenue Breakdown
Currency: USDUpdated: Mon, Apr 6
Currency: USDUpdated: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Voxzogo
926.92M
29.26%
Vimizim
792.05M
25.00%
Naglazyme
485.40M
15.32%
Palynziq
433.31M
13.68%
Aldurazyme
208.51M
6.58%
Other
321.57M
10.15%
By RegionUSD
Name
Revenue
Proportion
United States
1.10B
34.88%
Europe
874.33M
27.60%
Rest of the world
544.47M
17.19%
Latin America
435.48M
13.75%
ALDURAZYME net product revenues marked by Sanofi
208.51M
6.58%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Voxzogo
926.92M
29.26%
Vimizim
792.05M
25.00%
Naglazyme
485.40M
15.32%
Palynziq
433.31M
13.68%
Aldurazyme
208.51M
6.58%
Other
321.57M
10.15%
